The trial is testing the product as a potential treatment for synovial sarcoma, a cancer that appears in soft tissue, and SMARCB1-deleted tumors. Foghorn halted the trial after a “grade 4 QTc prolongation event in a synovial sarcoma patient at the second highest dose,” meaning the cancer patient’s heartbeat slowed or took longer than normal to contract and relax.
“[The] FDA placed the study on partial clinical hold in the United States, while allowing patients currently enrolled and benefiting from therapy to continue dosing and to remain on FHD-609,” Foghorn said, adding it “is not at this time planning to pursue a dose expansion study independently.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
